Chlorin E6-photodynamic therapy basal cell carcinoma

Purpose of the study. Evaluation of the therapeutic efficacy of chlorin E6-photodynamic therapy (PDT) with photosensitizers (PS) photoditazine, photolone and photoran in patients suffering basal cell skin carcinoma.

Materials and methods. The efficacy of chlorin E6-PDT was studied in 532 patients with basal cell skin cancer (BCC) aged 28 to 93 years. PhS Photoditazine was used in 72 (13,5 %) patients at a dose of 0.5-1.0 mg/kg, PhS Photolon - in 281 (52,8 %) patients at a dose of 1.1-1.6 mg/kg and PhS Photoran - in 179 (33,6 %) people at a dose of 1.1-1.6 mg/kg.

Sessions of local irradiation of tumor foci were performed on a laser device "Latus-2" (662 nm) with a power density of 200-500 mW/cm², light energy was applied to the tumors at a dose of 100-300-600 J/cm².

Results. During the follow-up period from 6 months to 5 years, 16.2 % of cases of relapse were diagnosed in the study group. When analyzing the results, it was found that the percentage of relapses was minimal when using all PhS in patients who underwent PDT for the first time established BCC of the initial stages (neoplasms up to 2.0 cm) and amounted to 2.2 % (4 patients out of 183), and with a prevalence of the process of more than 2.0 cm and up to 4.0 cm, 9.5 % (10 patients out of 105) of relapses were found. In the results of treatment of recurrent skin malignancies with PDT using derivatives of chloride E6, depending on the prevalence of the process, a similar trend was observed: with the size of tumor foci up to 2.0 cm, the percentage of repeated relapses was less and amounted to 17.1 % (18 patients out of 105) than in the treatment of neoplasms more than 2.0 cm and up to 4.0 cm (28.8 % of relapses - 21 patients out of 73).

Conclusions. Chlorin E6-PDT makes it possible to effectively treat primary and recurrent BCC in an independent variant, and the results of treatment depend on a number of factors, including the prevalence of the disease and the presence or absence of previous treatment.

1. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Ed. by Kaprin AD, Starinsky VV, Petrova GV. Moscow: P. A. Herzen Moscow State Medical Research Institute - branch of FSBI ”NMIC of Radiology” of the Ministry of Health of Russia. 2020, 252 p. (In Russ.).

2. Cameron MC, Lee E, Hibler BP, Barker CA, Mori S, Cordova M, et al. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019 Feb;80(2):303-317. https://doi.org/10.1016/jjaad.2018.03.060

3. Castrisos G, Lewandowski R. Narrative review of the epidemiology/biology of basal cell carcinoma: a need for public health consensus. ANZ J Surg. 2021 Jun;91(6):1098-1103. https://doi.org/10.1111/ans.16522

4. Berking C, Hauschild A, Kolbl O, Mast G, Gutzmer R. Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch Arztebl Int. 2014 May 30;111(22):389—395. https://doi.org/10.3238/arztebl.2014.0389

5. Agostinis P, Berg K, Cengel KA, Foster TH, Giroffi AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011 Aug;61(4):250—281. https://doi.org/10.3322/caac.20114

6. Dolmans DEJGJ, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003 May;3(5):380-387. https://doi.org/10.1038/nrc1071

7. Gamayunov SV, Korchagina KS. Local therapeutic methods for basal cell carcinoma. Effective Pharmacotherapy.2016;(39):74-83.

8. Trukhacheva TV, Shlyakhtin SV, Isakov GA, Istomin YuP. Photolon is a new tool for photodynamic therapy. Minsk, RUE "Belmed-preparaty”. 2009, 64 p.

9. Shlyakhtin SV, Trukhacheva TV, Isakov GA, Fedoruk SL, Semak IV. Pharmacokinetics and bioavailability of photolon photosensitizer (experimental study). Bulletin of BSU. Series 2: Chemistry. Biology. Geography. 2011;(1):62-68.

10. Chan Thi Hai Yen, Ramenskaya GV, Oborotova NA. Chlorin derivatives in cancer photodynamic therapy. Russian Biotherapeutic Journal. 2009;8(4):99—105.

11. Titov KS, Krasnorutskiy AV, Nagaeva MV. Non-surgical treatment of basal cell skin cancer. Russian Journal of Clinical Dermatology and Venereology. 2019;18(1):13-17. (In Russ.). https://doi.org/10.17116/klinderma20191801113

12. Volgin VN, Stranadko EF, Kagoyants RV. Results of treatment of various morphological types of skin cancer of ENT organs by photodynamic therapy. Saratov Journal of Medical Science 2014;10(3):555-558. (In Russ.).

13. Stranadko EPh, Riabov MV, Duvansky VA. Photodynamic therapy in the treatment of critical localizations of skin cancer. Bulletin of postgraduate medical education. 2019;(1):118-121. (In Russ.).

14. Filonenko EV. Physical methods in the treatment of skin cancer patients. Medical Technologies. Evaluation and Selection. 2012;(2(8)):100—105. (In Russ.).

15. Tzerkovsky DA, Mazurenko AN, Petrovskaya NA, Artemyeva TP. Photodynamic therapy with photosensitizer photolon for basal cell carcinoma. Biomedical Photonics. 2017;6(1):12-19. (In Russ.). https://doi.org/10.24931/2413-9432-2017-6-1-12-19

16. Kaplan MA, Kapinus VN, Yaroslavtseva-Isayeva EV, Spichenkova IS, Shubina AM, Borgul OV, et al. Photodynamic therapy: development of methods and clinical applications in FSI MRRC MOH. Photodynamic Therapy and Photodyagnosis. 2014;3(1):8-15. (In Russ.).

17. Kapinus VN, Kaplan MA, Sokol NI, Yaroslavtseva-Isayeva EV, Spichenkova IS, Kaprin AD, et al. Predictors of basal cell skin cancer recurrences after photodynamic therapy with Photolon photosensitizer. Laser Medicine. 2019;23(4):28-37. (In Russ.). https://doi.org/10.37895/2071-8004-2019-23-4-28-37

18. Kapinus VN, Kaplan MA, Yaroslavtseva-Isayeva EV, Spichenkova IS. Photodynamic therapy for head and neck basal cell skin cancer with additional interstitial laser irradiation. Biomedical Photonics. 2017;6(4):20-26. (In Russ.). https://doi.org/10.24931/2413-9432-2017-6-4-20-26

19. Kapinus VN, Kaplan MA, Spichenkova IS, Iaroslavtseva-Isaeva EV, Shubina AM, Goranskaia EV. Possibilities of photodynamic therapy in the treatment of recurrent basal cell carcinoma. P.A. Herzen Journal of Oncology. 2013;2(4):40-44. (In Russ.).

20. Kapinus VN, Kaplan MA. Photodynamic therapy and fluorescent diagnostics of skin basal cell carcinoma. Clinical dermatology and Venereology. 2011;9(2):48-52. (In Russ.).

21. Braunstein S, Nakamura JL. Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk. Front Oncol. 2013;3:73. https://doi.org/10.3389/fonc.2013.00073